In this report, the Psoriasis Therapeutics Market has been segmented by Type, Drug Class, Route of Administration, Dosage Forms, and Geography.

Psoriasis Therapeutics Market, Segmentation by Type

The Global Psoriasis Therapeutics Market has been segmented by Type into Plaque Psoriasis, Psoriatic Arthritis, and Others.

Plaque Psoriasis

Plaque psoriasis remains the most common form of the condition, representing approximately 80–90% of global psoriasis cases. Characterized by raised, scaly, and inflamed skin plaques, it significantly affects patients' quality of life. In 2022, the plaque psoriasis segment held a substantial market share of about 50.1%, with growth driven by the rising use of biologic therapies and innovative targeted treatments. Projections indicate a CAGR of 8.5% through 2032, underscoring the segment's robust expansion potential.

Psoriatic Arthritis

Psoriatic arthritis, affecting approximately 20–30% of psoriasis patients, involves both skin and joint inflammation. This segment is witnessing notable growth, valued at around USD 11.30 billion globally in 2023 and expected to reach USD 25.89 billion by 2034, reflecting a CAGR of 7.83%. Factors contributing to this expansion include the increasing recognition of joint-related symptoms and the introduction of advanced biologic therapies that improve patient outcomes.

Others

The 'Others' category covers rarer forms of psoriasis such as guttate, inverse, pustular, and erythrodermic psoriasis. Although these types represent a smaller portion of the market, they can present with severe symptoms requiring specialized care. The segment is gradually expanding, supported by ongoing research and the development of novel therapeutic options aimed at addressing the specific challenges posed by these less common forms.

Overall, the global psoriasis therapeutics market is set for continued growth, driven by innovations in treatment, rising disease prevalence, and increasing focus on personalized approaches that cater to different psoriasis subtypes.

Psoriasis Therapeutics Market, Segmentation by Drug Class

The Global Psoriasis Therapeutics Market has been segmented by Drug Class into TNF-Alpha Inhibitors, Interleukin Inhibitors, and Others.

TNF-Alpha Inhibitors

TNF-alpha inhibitors continue to be a mainstay in psoriasis treatment, contributing to approximately 41% of the global market share as of 2024. These biologics, including adalimumab, etanercept, and infliximab, work by blocking the tumor necrosis factor-alpha cytokine, thereby reducing skin inflammation. Their proven effectiveness and established safety profiles have cemented their role, although the rising popularity of newer therapies is starting to shift market dynamics.

Interleukin Inhibitors

Interleukin inhibitors are rapidly gaining traction in the psoriasis therapeutics landscape, with a projected CAGR of 12.2% over the forecast period. These treatments, targeting specific cytokines such as IL-17 and IL-23, are recognized for delivering superior efficacy and safety. The increasing adoption of biologics like secukinumab and risankizumab underscores a broader trend toward targeted approaches in managing moderate to severe psoriasis cases.

Others

The ‘Others’ category includes diverse therapies such as corticosteroids, vitamin D analogs, and Janus kinase (JAK) inhibitors. Primarily used for treating mild to moderate psoriasis, these options collectively represent a smaller portion of the overall market. However, ongoing research and advancements are opening new opportunities to integrate these treatments into more comprehensive psoriasis management strategies.

As the global psoriasis therapeutics market continues to expand, evolving drug classes, enhanced treatment efficacy, and a focus on patient-centric solutions are set to reshape the landscape and deliver better outcomes for patients worldwide.

Psoriasis Therapeutics Market, Segmentation by Route of Administration

The Psoriasis Therapeutics Market has been segmented by Route of Administration into Oral, Parenteral/Systemic, and Topical.

Oral

The oral route offers a convenient approach for delivering psoriasis treatments, particularly in cases of mild to moderate disease. Medications like acitretin and deucravacitinib are widely used for their systemic effects when topical treatments prove insufficient. Although the oral segment holds a smaller share compared to parenteral options, it remains a key component of comprehensive psoriasis management strategies, providing effective relief with easier administration.

Parenteral/Systemic

The parenteral or systemic route dominates the psoriasis therapeutics market, contributing approximately 41.58% to the total share in 2024. This is largely due to the widespread adoption of advanced biologic therapies like secukinumab, risankizumab, and guselkumab, known for their efficacy in moderate to severe psoriasis. These treatments offer rapid symptom control and targeted mechanisms of action, making them the preferred choice for both patients and healthcare providers.

Topical

The topical route remains the first-line option for managing mild psoriasis, providing targeted application with minimal systemic absorption. Treatments such as corticosteroids, vitamin D analogs, and retinoids are commonly used in this segment. Although it holds a smaller market share compared to parenteral therapies, the topical segment is expected to grow due to advancements in formulation technologies and the development of combination therapies that enhance both efficacy and patient adherence.

Overall, the psoriasis therapeutics market continues to evolve, with each route of administration offering unique benefits that cater to patient needs and disease severity. Ongoing innovations are expected to further diversify treatment options and improve outcomes for individuals with psoriasis worldwide.

Psoriasis Therapeutics Market, Segmentation by Dosage Forms

The Global Psoriasis Therapeutics Market has been segmented by Dosage Forms into Liquid, Semi-Solid, and Solid.

Liquid

Liquid formulations, including solutions and suspensions, are commonly used for topical applications and injectable treatments in psoriasis care. These forms are valued for their rapid absorption and ease of use, especially in treating acute flare-ups or conditions like scalp psoriasis. Although representing a smaller market share than semi-solid formulations, liquid forms play a crucial role in specific clinical scenarios.

Semi-Solid

Semi-solid formulations, such as creams, ointments, gels, and lotions, dominate the psoriasis therapeutics market, accounting for approximately 60% of the total market share in 2024. Their success stems from ease of application, targeted delivery, and strong patient adherence. Widely prescribed for localized plaque psoriasis, these treatments remain the go-to choice for mild to moderate cases, supporting consistent market growth.

Solid

Solid dosage forms, such as tablets and capsules, are primarily used for systemic therapies to manage moderate to severe psoriasis. Offering precise dosing and patient convenience, solid forms remain a vital option for long-term management. While holding a smaller market share than semi-solids, advances in oral systemic treatments are enhancing their role in comprehensive psoriasis care strategies.

The global psoriasis therapeutics market continues to evolve, driven by the availability of diverse dosage forms that cater to different patient needs and disease severities. Ongoing innovations are expected to further enhance treatment outcomes and expand market opportunities worldwide.

Psoriasis Therapeutics Market, Segmentation by Geography

In this report, the Psoriasis Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Psoriasis Therapeutics Market Share (%), by Geographical Region

North America

North America holds the leading position in the psoriasis therapeutics market, capturing approximately 39% of the global revenue share as of 2024. The region’s dominance is driven by a high prevalence of psoriasis, an advanced healthcare infrastructure, and the widespread adoption of biologic therapies. The United States, with an estimated 7.5 million psoriasis patients, plays a pivotal role in market growth. Strong research and development initiatives and supportive reimbursement policies further enhance North America’s market position.

Europe

Europe commands a significant share of the psoriasis therapeutics market, contributing around 30% in 2024. Growth is propelled by increasing awareness of psoriasis management, early diagnosis programs, and the adoption of advanced biologic treatments. Leading countries include Germany, the United Kingdom, and France, all supported by robust healthcare systems and favorable government initiatives that expand patient access to novel therapies.

Asia Pacific

The Asia Pacific region is emerging as the fastest-growing market for psoriasis therapeutics, with a projected CAGR of 11% from 2025 to 2034. Key drivers include a large patient population, rising healthcare investments, and growing awareness of dermatological conditions. Countries such as China, India, and Japan are spearheading this growth, with expanded healthcare infrastructure and the introduction of more affordable treatment options contributing to the region’s upward trajectory.

Middle East and Africa

The Middle East and Africa region, representing approximately 5% of the global market in 2024, is witnessing gradual growth due to improving healthcare access, increased awareness initiatives, and the rising availability of advanced treatments. Urban areas in countries like Saudi Arabia, the UAE, and South Africa are seeing higher demand for effective psoriasis therapies, supported by local investments in healthcare delivery and infrastructure.

Latin America

Latin America accounts for an estimated 6% of the global psoriasis therapeutics market in 2024. The region’s growth is driven by increasing disease prevalence, enhanced healthcare services, and the introduction of new treatment options. Brazil and Mexico